Neoadjuvant Nivolumab in Resectable Non-Small-Cell Lung Cancer
Status:
Recruiting
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
The proposed study will evaluate the safety and feasibility of preoperative administration
nivolumab in patients with high-risk resectable NSCLC, and will facilitate a comprehensive
exploratory characterization of the tumor immune milieu and circulating immune cells and
soluble factors in these patients. Data obtained in this study will provide valuable
information for planning further prospective clinical trials of anti-PD-1 and other
immunotherapies in NSCLC, both in the peri-operative and advanced disease setting.
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University